RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kazia Therapeutics Stock

Kazia Therapeutics P/E 2025

Kazia Therapeutics P/E

4.41

Ticker

KZA.AX

ISIN

AU000000KZA9

WKN

A2H8QW

As of Jun 22, 2025, Kazia Therapeutics's P/E ratio was 4.41, a 0% change from the 0 P/E ratio recorded in the previous year.

The Kazia Therapeutics P/E history

Kazia Therapeutics Aktienanalyse

What does Kazia Therapeutics do?

Kazia Therapeutics Ltd is an Australian biotechnology company that specializes in the development and commercialization of novel therapeutics for the treatment of cancer and other neurological diseases. Founded in 2003 as NeuTools, the company was renamed Kazia Therapeutics in 2013, focusing on the development of cancer drugs. Kazia Therapeutics' business model is based on the use of groundbreaking sciences, such as Polycomb inhibitors, which have been identified as critical targets in cancer treatment. Kazia Therapeutics specializes in developing drugs that have higher efficacy against cancer than conventional treatments. The company has a strong pipeline of products, including Cantrixil, GDC-0084, and EVT801. Cantrixil is a drug developed for the treatment of advanced ovarian cancer. It differs from traditional chemotherapy by specifically binding to cancer cells and targeting them. In clinical trials, Cantrixil has shown promising results and is now in Phase III of clinical development. The second important product of Kazia Therapeutics is GDC-0084, which was developed as a brain tumor drug and is currently in Phase II of clinical development. GDC-0084 uses a new technology that allows the drug to be delivered directly to the brain tumor. EVT801 is a new drug being developed in collaboration with Massachusetts General Hospital. It is used for the treatment of Parkinson's disease and has the potential to be an effective alternative to existing medications. Kazia Therapeutics has partnerships with leading academic institutions and pharmaceutical companies such as Novartis, AstraZeneca, and Genentech to create synergies and bring the pipeline to market. The company is based in Sydney, Australia, and employs a small but passionate and experienced leadership team with a strong track record in the biopharmaceutical industry. Overall, Kazia Therapeutics is an innovative biotechnology company that relies on groundbreaking sciences to develop new therapies for the treatment of cancer and neurological diseases. With its promising products and partnerships, the company has the potential to improve the lives of millions of people worldwide. Kazia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Kazia Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Kazia Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Kazia Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Kazia Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Kazia Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Kazia Therapeutics stock

What is the price-to-earnings ratio of Kazia Therapeutics?

The price-earnings ratio of Kazia Therapeutics is currently 4.41.

How has the price-earnings ratio of Kazia Therapeutics changed compared to last year?

The price-to-earnings ratio of Kazia Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Kazia Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Kazia Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Kazia Therapeutics affect the company?

An increase in the price-earnings ratio of Kazia Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Kazia Therapeutics affect the company?

A decrease in the price-earnings ratio of Kazia Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Kazia Therapeutics?

Some factors that influence the price-earnings ratio of Kazia Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Kazia Therapeutics pay?

Over the past 12 months, Kazia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kazia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Kazia Therapeutics?

The current dividend yield of Kazia Therapeutics is .

When does Kazia Therapeutics pay dividends?

Kazia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kazia Therapeutics?

Kazia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kazia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kazia Therapeutics located?

Kazia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kazia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kazia Therapeutics from 6/22/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/22/2025.

When did Kazia Therapeutics pay the last dividend?

The last dividend was paid out on 6/22/2025.

What was the dividend of Kazia Therapeutics in the year 2024?

In the year 2024, Kazia Therapeutics distributed 0 AUD as dividends.

In which currency does Kazia Therapeutics pay out the dividend?

The dividends of Kazia Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kazia Therapeutics

Our stock analysis for Kazia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kazia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.